Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study

被引：1

作者：

Gavriatopoulou, Maria ^{[1
]}

Vogl, Dan T. ^{[2
]}

Nooka, Ajay ^{[3
]}

Dingli, David ^{[4
]}

Cole, Craig ^{[5
]}

Moreau, Philippe ^{[6
]}

Huff, Carol ^{[7
]}

Yee, Andrew ^{[8
]}

Dimopoulos, Meletios A. ^{[9
]}

Lonial, Sagar ^{[10
]}

Richardson, Paul G. ^{[11
]}

Stewart, Keith ^{[12
]}

Chari, Ajai ^{[13
]}

Richter, Joshua ^{[14
]}

Biran, Noa ^{[14
]}

Siegel, David S. ^{[15
]}

Liu, Jianjun ^{[16
]}

Joshi, Anita ^{[16
]}

Shah, Jatin ^{[16
]}

Shacham, Sharon ^{[16
]}

Kauffman, Michael ^{[16
]}

Jagannath, Sundar ^{[17
]}

机构：

[1] Univ Athens, Sch Med, Athens, Greece

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[4] Mayo Clin, Rochester, MN USA

[5] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[6] CHU Nantes, Univ Hosp Hotel Dieu HME, Nantes, France

[7] Johns Hopkins Univ, Baltimore, MD USA

[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[9] Univ Athens, Sch Med, Alexandra Hosp, Athens, Greece

[10] Emory Univ, Atlanta, GA 30322 USA

[11] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[12] Mayo Clin, Scottsdale, AZ USA

[13] Mt Sinai Sch Med, New York, NY USA

[14] Hackensack Univ, John Theurer Canc Ctr, Hackensack, NJ USA

[15] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA

[16] Karyopharm Therapeut Inc, Newton, MA USA

[17] Mt Sinai Hosp, New York, NY 10029 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

Elderly patients; novel agents; relapsed/refractory multiple myeloma;

D O I：

10.1016/j.clml.2019.09.195

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

FP-110

引用

页码：E117 / E118

页数：2

共 50 条

[21] Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
Chen, Christine I.
Bahlis, Nizar
Gasparetto, Cristina
Tuchman, Sascha A.
Lipe, Brea C.
Baljevic, Muhamed
Kotb, Rami
Sutherland, Heather J.
Bensinger, William I.
Sebag, Michael
Leblanc, Richard
Venner, Christopher P.
Schiller, Gary J.
Lentzsch, Suzanne
Callander, Natalie Scott
Sheehan, Heidi
Chai, Yi
Kai, Kazuharu
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
White, Darrell J.
BLOOD, 2019, 134
[22] African American relapsed/refractory multiple myeloma patients have a progression free survival benefit with selinexor treatment in the STORM study
Cole, Craig
Opalikhin, Anne
McCartney, Matthew
Heideman, Caroline
Pentapati, Swetha
Wang, Ling
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S168 - S169
[23] Safety and Efficacy of Bortezomib in Refractory/Relapsed Multiple Myeloma
Lalagianni, C. E.
Neokleous, N.
Vadikoliou, C.
Papalexandri, A.
Apostolou, C.
Saloum, R.
Anagnostopoulos, A.
Fassas, A.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S26 - S26
[24] The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
贾亚静
China Medical Abstracts(Internal Medicine), 2020, 37 (03) : 189 - 189
[25] Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
Alegre, Adrian
Vicuna, Isabel
Aguado, Beatriz
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
[26] Racial differences in outcomes of patients with relapsed/refractory multiple myeloma treated with selinexor
Cole, Craig
Opalikhin, Anne Maria
McCartney, Matthew
Heideman, Caroline
Pentapati, Swetha
Wang, Ling
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma
Berenson, James R.
Martinez, Daisy
Safaie, Tahmineh
Silagan, Noemi
To, Jennifer
Spektor, Tanya M.
Forouzan, Eli
Swift, Regina
Eades, Benjamin
Eshaghian, Shahrooz
Schwartz, Gary
Boccia, Ralph V.
Yang, Honghao H.
Moezi, Mehdi M.
Lim, Stephen
Vescio, Robert
BLOOD, 2021, 138
[28] Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Suvannasankha, Attaya
Bahlis, Nizar
Trudel, Suzanne
Weisel, Katja
Koenecke, Christian
Oriol, Albert
Voorhees, Peter M.
Alonso, Aranzazu A.
Callander, Natalie S.
Mateos, Maria-Victoria
Reddy, Nishitha
Hakim, Shawn
Lamacchia, John
Patel, Nashita
Williams, Danae
Jewell, Roxanne. C.
Zhou, Xiangdong
Gupta, Ira
Opalinska, Joanna
Nooka, Ajay K.
CANCER, 2024, 130 (15) : 2629 - 2641
[29] Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study
Schuster, Michael W.
Canales, Miguel A.
Westin, Jason
Zijlstra, Josee M.
Follows, George A.
Karmali, Reem
Kalakonda, Nagesh
Goy, Andre H.
Casasnovas, Rene-Olivier
Vermaat, Joost
Van den Neste, Eric
Choquet, Sylvain
Thieblemont, Catherine
Cavallo, Federica
De La Cruz, Maria de Fatima
Hill, Brian T.
Tilly, Herve
Kassam, Shireen
Bouabdallah, Reda
Jaeger, Ulrich
Gurion, Ronit
Caimi, Paolo
Martin, Peter
Davies, Andrew
Smith, Sonali M.
Collins, Graham P.
Offner, Fritz C.
Salles, Gilles
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita A.
Chamoun, Kamal
Wang, Hongwei
Shah, Jatin J.
Shacham, Sharon
Kauffman, Michael G.
Maerevoet, Marie
BLOOD, 2020, 136
[30] EFFECTIVENESS AND SAFETY ANALYSIS OF DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Kumar, Seri A.
Fe, Bitaube R.
Hinojosa, Orantos C.
Gavira, Moreno R.
Garzon, Lopez S.
HAEMATOLOGICA, 2021, 106 (10) : 339 - 340

← 1 2 3 4 5 →